Charta Health's $55M Series B, led by Insight Partners, funds a push from provider billing into payer-side coding, lifting total capital raised to $85M.
Key Takeaways
- Charta Health raised $55M in Series B funding on November 10, 2026, led by Insight Partners.
- Total funding reaches $85M across three rounds in under two years; valuation was not disclosed.
- The company launched Charta for Payers alongside its provider product and reports 10x revenue growth in 12 months.
Lead
Charta Health, a San Francisco startup that uses AI to review medical charts against billing codes, announced a $55M Series B on November 10, 2026. Insight Partners led the round. Existing investors Madrona, Bain Capital Ventures, South Park Commons and QuantumLight Software also participated. The company did not disclose its valuation.
The raise brings Charta's total funding to $85M. That is roughly 2.8 times the $30.1M it had raised through its seed and Series A rounds, and it arrives about 16 months after the $22M Series A led by Bain Capital Ventures in mid-2025.
What Does Charta Health Actually Do?
Charta reads clinical documentation, including physician notes, scanned orders, lab results and images, and checks whether the documented care supports the codes submitted for billing. The company advertises 98% accuracy on diagnosis coding, achieved by pairing AI evidence retrieval with human validation.
Its provider product reviews charts before a claim goes out. It tests them against coding guidelines and payer rules, then surfaces findings inside the electronic health record for a human to approve. The aim is fewer denials and less exposure to clawbacks after payment.
Founders Justin Liu (CEO) and Scott Morris (CTO) both came from Rockset, the database startup OpenAI acquired. They spent a year earning Certified Professional Coder credentials before building the product. Charta says its engineering and growth staff must obtain coding certification too.
Why Is Charta Moving Into Payer Coding?
Charta launched Charta for Payers with this round because insurers face the same chart-accuracy problem from the other side of the claim. The payer product covers retrospective HCC coding, an AI-automated second-pass coding review, prospective risk adjustment intelligence, HCC validation and audit workflows, and HEDIS quality care-gap detection.
The company's stated goal is a single agreed reading of a chart before billing, shared by provider and payer. That is a commercial bet as much as a technical one. Selling to both sides of a dispute can produce a neutral standard, or it can produce a conflict of interest in the eyes of customers on either side. Charta has not said how it will separate the two products' data or incentives.
What Does the Round Say About the Last One?
The Series B shows that the Series A thesis held up commercially. Charta reports 10x revenue growth over the past 12 months, though it did not publish revenue figures. Named provider customers include American Family Care, Grow Therapy and the Pediatric Associates Family of Companies.
A lead change is also visible. Bain Capital Ventures led the seed and Series A, while Insight Partners, a later-stage growth investor, now leads. Existing backers stayed in, which signals support from insiders rather than a full repricing by outsiders. Without a disclosed valuation, the size of the step-up cannot be judged.
Three rounds in under two years is fast, and it reflects investor appetite for AI tools that attach to revenue-cycle workflows with measurable dollar outcomes. It also means Charta must now show that growth from early adopters in outpatient and behavioral health carries over to larger health systems and insurers, which have longer sales cycles.
Who Else Is Working on Medical Coding Automation?
Charta competes in a field that includes established revenue-cycle vendors and a growing set of AI coding startups. Differentiation rests on accuracy claims that buyers must verify themselves. A 98% figure on diagnosis coding is meaningful only against a stated benchmark, and the company has not published the dataset or methodology behind it.
What Will the Money Fund?
Charta plans to spend the capital on three things: faster AI research and development, the commercial rollout of its provider and payer products, and expansion of the provider offering into additional medical specialties. Each specialty carries its own coding rules and documentation habits, so the expansion is likely to be gradual, and accuracy will need to be shown again in each one.
Outlook
Charta enters 2027 with $85M raised, a new payer product and customer growth it describes as tenfold. The open questions are valuation, absolute revenue, and whether one vendor can serve both providers and insurers without compromising trust on either side. Results from larger health system and payer deployments will show whether the shared-standard pitch holds up outside its early customer base.



